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Abstract
Purpose—To evaluate the effectiveness of a policy supporting early detection and prevention of 
cervical cancer among low-income and uninsured women by comparing women who reported 
never or rarely being screened (last screen >5 years) to those who reported screening in the past ≤5 
years.
Methods—We analyzed data from 1,485,251 women who received their first Pap test in the 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP) from July 2002 
through June 2012. Of these, 461,893 women (31 %) reported being never or rarely screened and 
1,023,358 (69 %) reported being screened in the past 5 years. Demographic (age, race/ethnicity, 
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residence, and region) and clinic (cytologic and histologic results) characteristics were examined 
for the two groups.
Results—Women who were aged ≥50 years, Asian and Pacific Islander, American Indian or 
Alaska Native, multiracial, living in non-metro areas, or living in the South or a territory were 
more likely to report being never or rarely screened. The percentage of abnormal Pap tests and the 
rate of precancer and cancer (combined) was higher in the never or rarely screened group 
compared with the screened group (abnormal percentage: 2.9 vs 2.6 %, p value < 0.01; rate of 
precancer and cancer: 6.9 vs 3.7 per 1,000 women, p value < 0.01).
Conclusions—The priority of reaching never or rarely screened women should continue since 
those women who entered the NBCCEDP not adequately screened had a greater prevalence of 
high-grade histological lesions and invasive cervical cancers at later stages than women screened 
more recently.
Keywords
Pap test; Mass screening; Cervix neoplasms
Introduction
Cervical cancer screening has resulted in well-documented declines in cervical cancer 
incidence and mortality in the USA [1]. However, in 2011, there were still almost 12,000 
women who developed cervical cancer and 4,000 women who died from this disease [2]. It 
is estimated that more than half of women who develop cervical cancer were not screened or 
were not screened appropriately [3, 4]. In 2010, 83 % of women reported having a Pap test 
within the past 3 years [5], significantly lower than the Healthy People 2020 target of 93 % 
[6].
To improve cervical cancer screening among medically underserved women, Congress 
authorized the Centers for Disease Control and Prevention (CDC) to develop the National 
Breast and Cervical Cancer Early Detection Program (NBCCEDP). In 1999, CDC 
intensified the policy to focus their efforts and resources on those who would benefit the 
most from screening: never or rarely screened women (last screen >5 years previously) (NR) 
who were at the highest risk of developing cervical cancer.
Clinical outcomes of this population have not been studied previously to evaluate the 
effectiveness of the NBCCEDP’s policy on early detection and prevention of cervical 
cancer. We describe the population of women in the NBCCEDP who reported being NR, 
compare them to women with prior screening, and describe patient demographics and 
prevalence of cervical cancer screening results by screening history across a 10-year period 
to assess long-term outcomes of this national cervical cancer screening program.
Methods
CDC implemented cooperative agreements with all states, the District of Columbia, 
American Indian/Alaska Native tribes, and territories to provide cancer screening, referral, 
and follow-up services to low-income, uninsured, and underinsured women; these have been 
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described in detail elsewhere in this supplement [7]. For this study, we examined data 
submitted by 50 states, the District of Columbia, 12 tribes, and five territories during July 
2002 through June 2012. The study was approved by CDC’s Human Subjects Committee.
Study population
The study cohort comprised women who were newly enrolled in the NBCCEDP and had 
received their first NBCCEDP Pap test, and allowed at least 6 months for a diagnostic work-
up to be completed after abnormal findings. Of the 1,684,272 women receiving an initial 
NBCCEDP Pap test, we eliminated 199,021 (12 %) from the analysis because of missing or 
unknown screening history, leaving a study population of 1,485,251 (Fig. 1). The women 
who were not included (12 %) had similar characteristics and screening results as the study 
population. During the study period, there were 1,023,358 women (69 %) who reported a 
Pap test within 5 years and 461,893 women (31 %) reporting never or rarely being screened 
(38 % were never screened and 62 % had their last screen >5 years defined as rarely); in 
both groups (screened and NR), 4 % of the Pap tests required diagnostic follow-up, 
including colposcopy with biopsy.
Study outcomes
Abnormal Pap test results that signaled the need for additional diagnostic testing included 
low-grade squamous intraepithelial lesions, atypical squamous cells—cannot exclude high-
grade squamous intraepithelial lesion, highgrade squamous intraepithelial lesion, squamous 
cell cancer, and atypical glandular cells. In 2003, when the Food and Drug Administration 
approved the human papillomavirus (HPV) test to screen for cervical cancer in conjunction 
with the Pap test (known as co-testing), the NBCCEDP reimbursed for management only 
(known as reflex testing) [8]. However, reflex HPV testing was not systematically captured 
in the data system until 2009 [9]. Reimbursement for co-testing began in 2012 when the US 
Preventive Services Task Force recommended co-testing as an option for cervical cancer 
screening [10].
For the present study, we calculated age based on the birth date reported at enrollment and 
used six age classifications: 18–20, 21–29, 30–39, 40–49, 50–64, and ≥65 years. The age 
groups were selected after consideration of age-related influences on screening rates, such as 
Medicare coverage primarily for those aged ≥65 years and changes in the screening 
recommendations for younger women not to be screened (aged < 21 years) [11]. To 
categorize residence at the time of screening as metropolitan, urban, or rural, the rural/urban 
continuum codes were used [12].
We calculated the percentages of Pap test results by screening history, defined as screening 
in the past 5 years (P5Y) or never/rarely being screened (NR) defined as never screened or 
not in the past 5 years. We computed detection rates for each grade of cervical intraepithelial 
neoplasia (CIN) and invasive cancer as the number of cases with a final histologic diagnosis 
of CIN (CIN1, CIN2, CIN3/carcinoma in situ) or invasive cancer per 1,000 Pap tests 
performed, by screening history. To estimate the detection rate of high-grade lesions, we 
combined biopsy results of CIN3/carcinoma in situ, adenocarcinoma in situ, and invasive 
cancer (i.e., CIN3 or worse). Percentages and rates were age-adjusted by the direct method 
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using the distribution of the population receiving a Pap test through NBCCEDP in 2000. 
Logistic regression models were computed to examine predictors of NR screened women 
compared with P5Y women, adjusting for age.
Results
Table 1 shows the demographic characteristics of women who had their first Pap test in the 
NBCCEDP during 2002–2012, by screening history. Women in the NR screened group were 
older than those who reported being screened P5Y. Women in the NR screened group also 
were more likely to be white, Asian–Pacific Islander, American Indian/Alaskan Native, and 
multiracial. Geographically, women living in non-metro areas or in the South or a territory 
were more likely to report NR screened than to report being in the P5Y group.
The cytology results for women’s first Pap test in the NBCCEDP by age group and 
screening history are shown in Table 2. Women aged < 30 years in either screening history 
group had higher percentages of abnormal Pap test results (low-grade squamous 
intraepithelial lesions, atypical squamous cells—cannot exclude high-grade squamous 
intraepithelial lesions, and high-grade squamous intraepithelial lesions) than did women 
aged ≥30 years. Also, squamous cell carcinoma (from cytology) occurred at an earlier age 
(40 years old) and was more common in the NR population than in the P5Y population.
Overall, there were more women with abnormal Pap test results in the NR screened group 
than in the P5Y group (2.9 vs 2.6 %; p value < 0.05; Table 3). The percentage with 
abnormal Pap tests decreased with increasing age for both screening history groups; for 
women aged ≥40 years, the percentage of abnormal Pap tests was higher in the NR group 
compared with the P5Y group. The NR group had a higher abnormal Pap test prevalence in 
every race/ethnicity group, rural–urban category, and region compared with the P5Y group, 
with significant differences in prevalence noted in the Hispanic, metro, Midwest, Northeast, 
South and West.
Figure 2a–d shows the biopsy-confirmed histology results by age group. Younger women 
(aged < 30 years) had higher rates of CIN (1, 2, and 3) in the P5Y group compared with 
those in the NR group (Fig. 2a–c). However, the rate of invasive cancer increased with age, 
with higher rates in NR women compared with P5Y women, except among 21–29 years olds 
(Fig. 2d). The rates of CIN3 or worse were higher in the NR group than in the P5Y group 
overall and every characteristic group, except among younger women aged 18–29 years 
(Table 4). For women with invasive cervical cancer, those in the NR population had more 
cancers diagnosed at a late stage than did those in the P5Y group [SEER summary stage: 
localized 32 % NR compared with 45 % P5Y; distant 13 % NR compared with 7 % P5Y 
(data not shown)].
Discussion
The National Breast and Cervical Cancer Early Detection Program targeted never and rarely 
screened women for outreach as these women were presumed to benefit the most from 
screening, since they are at the highest risk of developing invasive disease. Our study 
demonstrated that this was an effective strategy for screening, because more NR women 
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developed invasive cancers at younger ages and at later stages than did women screened 
more frequently.
Our data showed that younger women had higher rates of abnormal Pap tests and high-grade 
lesions (CIN2 or 3), yet older women had higher rates of invasive disease. These findings 
are consistent with those of other population- based studies [13] and with the natural history 
of the disease [14]. However, percentages and rates of abnormal test results in the younger 
age groups in our study population were higher than in other studies (especially among P5Y 
women compared with NR women) [15] Of note is the higher rate of CIN3 or worse among 
younger women, especially women aged < 30 years in the P5Y screened group (12.9 per 
1,000 Pap tests among those aged 18–20 and 13.5 per 1,000 Pap tests among those aged 21–
29; Table 4). It is likely that the younger women in the P5Y group of our study population 
were referred to the NBCCEDP after obtaining an abnormal screening result elsewhere. 
Additionally prior to the 2012 recommendations, which included most of the time period for 
this study, women were screened depending on age and sexual activity [16] and thus 
(women ≤30 years) may represent a group at higher risk of HPV exposure [17]. Since the 
2012 recommendations against screening adolescents, the NBCCEDP has targeted women 
aged ≥30 years who reported being NR. We analyzed these data without including younger 
women aged < 30 years and found a much larger difference between the percentages of 
abnormal Pap tests and the rates of CIN and invasive disease among the women in the NR 
group compared with the P5Y group (data not shown).
Researchers at CDC conducted a review of the scientific literature, professional organization 
guidelines related to cervical cancer, and NBCCEDP data on Pap screening outcomes and 
collaborated on the development of the new cervical cancer screening policy. In 1999, 
NBCCEDP recommended that women who had three normal Pap tests could wait 3 years 
before their next routine screening. This policy recommendation was made before the 
national recommendations were changed in 2002 to wait 3 years between screenings [18]. In 
2005, NBCCEDP policy was incorporated as a core indicator within a CDC-administered 
performance management system to prioritize funding resources for NR women, with a goal 
that at least 20 % of women newly enrolled in the NBCCEDP for cervical screening should 
be NR [19]. Our data indicated that most NR women who came to the NBCCEDP were aged 
≥50 years, white, Asian–Pacific Islander, American Indian/Alaskan Native, or multiracial, 
and were living in nonmetro areas and in the South or a territory. Similarly, other studies 
have found that older women, racial minorities, and women living in rural areas in the South 
have a higher disease burden [20–23]. Therefore, more targeted efforts to screen these 
specific groups may be warranted to reach those at the highest risk of cervical cancer.
Many changes in the early detection and prevention of cervical cancer have occurred in the 
10 years of this study period, including the introduction of the HPV vaccine [24], the HPV 
test for screening [25], updates in reporting systems [26], and updates in recommendations 
for screening [10] and management [27]. Therefore, some interpretations of findings for 
both cytology and histology may differ depending on the year of outcome. Additionally, this 
study may be limited because of the lack of information on whether women had previously 
experienced abnormal results and been referred to NBCCEDP prior to 2009, when data 
collection was expanded to include the reason for the visit.
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The NBCCEDP is the only national screening program for cervical cancer in the USA, and 
ours is the first analysis focusing on women who had never or rarely been screened. Our 
findings of high-grade lesions and invasive cancers beginning at younger ages for NR 
women suggest that reaching this group before progression to invasive disease is essential to 
preventing and reducing cervical cancer incidence and mortality and that screening this 
group should continue to be a priority.
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Fig. 1. 
Study population of women receiving a first Pap test in the National Breast and Cervical 
Cancer Early Detection Program (NBCCEDP) by screening history and follow-up from 
2002–2012. NBCCEDP National Breast and Cervical Cancer Early Detection Program, NR 
never/rarely, P5Y screened in the past ≤5 years
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Fig. 2. 
Rates of cervical precancer and invasive cancer among women receiving their first Pap test 
in the National Breast and Cervical Cancer Early Detection Program, by screening history 
and age group, 2002–2012. a Rates per 1,000 women of CIN1 by screening history and age 
group (years). b Rates per 1,000 women of CIN2 by screening history and age group 
(years). c Rates per 1,000 women of CIN3* by screening history and age group (years). d 
Rates per 1,000 women of invasive cancer by screening history and age group (years). CIN 
cervical intraepithelial neoplasia, NR never or rarely (not screened within 5 years) screened, 
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P5Y screened within last 5 years. *CIN3 includes CIN3, carcinoma in situ, adenocarcinoma 
in situ
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Table 1
Demographic characteristics among women receiving a first Pap test in the National Breast and Cervical 
Cancer Early Detection Program, by screening history, 2002–2012
Total Screening history (n) Differenced (NR–P5Y %)
NR (%)
461,893 (100 %)
P5Y (%)
1,023,358 (100 %)
Age group (years)
18–20 7,866 (1.7) 11,890 (1.2) 0.5
21–29 28,489 (6.2) 69,523 (6.8) −0.6
30–39 41,878 (9.1) 108,966 (10.7) −1.6
40–49 173,820 (37.6) 414,599 (40.5) −2.9
50–59 159,036 (34.4) 325,157 (31.8) 2.7
60–64 44,549 (9.6) 84,537 (8.3) 1.4
≥65 6,255 (1.4) 8,686 (0.9) 0.5
Race/ethnicitya
White 225,462 (48.8) 465,589 (45.5) 3.3
African-American 61,792 (13.4) 144,648 (14.1) −0.8
Asian/Pacific Islander 39,128 (8.5) 47,110 (4.6) 3.9
American Indian/Alaska Native 22,218 (4.8) 32,495 (3.2) 1.6
Multiracial/unknownb 11,168 (2.4) 21,800 (2.1) 0.3
Hispanic 102,125 (22.1) 311,716 (30.5) −8.4
Rural–urbana
Metro 326,163 (70.6) 763,900 (74.6) −4.0
Urban 110,052 (23.8) 220,806 (21.6) 2.2
Rural 18,187 (3.9) 34,992 (3.4) 0.5
Unknown 7,491 (1.6) 3,660 (0.4) 1.3
Regiona, c
Territory 7,502 (1.6) 4,000 (0.4) 1.2
Northeast 79,579 (17.2) 203,761 (19.9) −2.7
Midwest 94,709 (20.5) 240,545 (23.5) −3.0
South 159,367 (34.5) 302,912 (29.6) 4.9
West 120,736 (26.1) 272,140 (26.6) −0.5
NR never or rarely (not screened within 5 years) screened, P5Y screened within 5 years
a
Percentages age-adjusted to the 2000 National Breast and Cervical Cancer Early Detection Program
bNR screened history for unknown race/ethnicity is 8,263 (1.8 %) and for P5Y is 16,589 (1.6 %)
c
Region: Territory (American Samoa, Guam, Commonwealth of Northern Mariana Islands, Republic of Palau, Puerto Rico, Virgin Islands); 
Northeast (Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont); Midwest 
(Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin); South (Alabama, 
Arkansas, Delaware, DC, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, 
Texas, Virginia, West Virginia); West (Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, 
Washington, Wyoming)
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d
p values computed from separate logistic models of screening history with age, race/ethnicity, rural–urban, or region as the covariate were all 
statistically different (<0.05)
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Table 3
Distribution (%) of abnormal cervical cancer screening results among women receiving their first Pap test in 
the National Breast and Cervical Cancer Early Detection Program, by screening history, 2002–2012
Totala Screening history Difference(NR–P5Y %)
NR P5Y
Total abnormal Pap testsb
(%)
2.9 2.6 0.3*
Age group (years)
18–20 8.8 15.3
−6.5*
21–29 8.0 10.8
−2.8*
30–39 4.6 4.6 −0.1
40–49 3.1 2.6 0.5*
50–59 2.3 1.8 0.5*
60–64 1.9 1.4 0.5*
≥65 2.1 1.5 0.6*
Race/ethnicitya
White 3.3 3.1 0.3
African-American 2.6 2.5 0.1
Asian/Pacific Islander 2.1 1.8 0.3
American Indian/Alaska Native 2.0 2.0 <0.1
Multiracial/unknown 2.4 2.3 0.1
Hispanic 2.6 2.1 0.5*
Rural–urbana
Metro 2.8 2.5 0.3*
Urban 3.1 2.9 0.2
Rural 3.1 2.7 0.3
Unknown 2.0 1.3 0.7*
Regiona
Territory 1.9 1.6 0.4
Northeast 2.7 2.5 0.3*
Midwest 3.5 3.3 0.2*
South 3.1 2.8 0.3*
West 2.4 2.0 0.4*
NR never or rarely (not screened within 5 years) screened, P5Y screened within last 5 years
*
p values significantly different at <0.05 from separate nested logistic models of abnormal Pap test with age, race/ethnicity, rural–urban, or region 
associated with screening history
a
Percentages age-adjusted to the 2000 National Breast and Cervical Cancer Early Detection Program
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b
Includes the following Pap test results: atypical glandular cells, atypical squamous cells of undetermined significance—cannot exclude high-grade 
squamous intraepithelial lesion, high-grade squamous intraepithelial lesion, and squamous cell carcinoma
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Table 4
Rates of cervical precancer and cancer among women receiving their first Pap test in the National Breast and 
Cervical Cancer Early Detection Program, by screening history, 2002–2012
Totala Screening history Difference(NR–P5Y %)
NR P5Y
Rate of CIN3 or worseb
per 1,000 women
6.9 3.7 3.2*
Age group (years)
18–20 3.7 12.9
−9.2*
21–29 8.7 13.5
−4.8*
30–39 10.7 8.3 2.4*
40–49 7.4 3.7 3.6*
50–59 5.9 2.4 3.5*
60–64 6.0 2.3 3.7*
≥65 7.4 4.7 2.6*
Race/ethnicitya
White 8.6 4.8 3.9*
African-American 5.3 3.3 2.0*
Asian/Pacific Islander 5.5 2.4 3.1*
American Indian/Alaska Native 4.4 2.7 1.7
Multiracial/unknown 4.7 3.8 0.9
Hispanic 5.4 2.9 2.5*
Rural–urbana
Metro 6.4 3.4 3.0*
Urban 8.2 4.6 3.6*
Rural 7.9 4.2 3.6*
Unknown 6.3 2.9 3.3*
Regiona
Territory 6.2 2.7 3.5
Northeast 5.8 3.0 2.9*
Midwest 8.7 5.0 3.7*
South 7.3 4.0 3.3*
West 6.4 3.3 3.1*
CIN cervical intraepithelial neoplasia, NR never or rarely (not screened within 5 years) screened, P5Y screened within last 5 years
*
p values significantly different at <0.05 from separate nested logistic models of CIN3 or worse, with age, race/ethnicity, residence, or region 
associated with screening history
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a
Percentages age-adjusted to the 2000 National Breast and Cervical Cancer Early Detection Program
bCIN3 or worse includes CIN3, carcinoma in situ, adenocarcinoma in situ, and invasive cervical cancer
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